ASCO 2021 | Phase I INSIGHT platform trial: eftilagimod alpha with avelumab in advanced solid tumors

Thorsten O. Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, discusses results from stratum D of the INSIGHT platform trial (NCT03252938), a Phase I study evaluating feasibility and safety of subcutaneous eftilagimod alpha, a soluble LAG-3 protein, in combination with avelumab in patients with advanced solid tumors. Combined treatment with avelumab and eftilagimod alpha seems feasible and safe, in addition, no unexpected adverse events occurred. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.